EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
WHO has asked manufacturers of mpox in vitro diagnostics (IVDs) to submit an expression of interest for Emergency Use Listing (EUL).
Share this article The revenue for Endoxifen is expected to reach an annual total of $58 mn by 2035 globally based off GlobalData’s Expiry Model.
Washington University School of Medicine in St. Louis has joined the Pediatric Heart Network, a multicenter collaboration of leading hospitals and research institutions that works